Incidence of human papillomavirus genotypes and estimated repercussion of quadrivalent vaccine in Cadiz, Spain
Abstract number: P1594
Cebada M., Blanco M., Popa I., Lozano A., Reyes M., Fernández C.
Objectives: Infection with human papillomavirus (HPV) as an essential cause of cervical cancer has now been established. The quadrivalent HPV vaccine protects against infections by HPV6, 11, 16 and 18.
HPV16 and HPV18 cause approximately 70% of cervical cancer worldwide so, the implementation of the HPV vaccine is a very important effort toward preventing high-grade cervical lesions.
The aim of the study was to know the incidence of different HPV genotypes and to estimate a possible repercussion of quadrivalent HPV vaccine in our sanitary area.
Methods: A total of 950 endocervical or vulvar swabs from woman suspicious of HPV infection (colposcopy and/or citology) were processed during 2006 to HPV detection. In 157 samples from 143 first visit patients (criteria for inclusion in the study) we detected any genotype of HPV. All samples were collected in duplicate and specimens were stored at 4°C for a maximum of 6 days before detection. HPV extraction, amplification and detection were carried out according to the manufacturer (PVHfast, Genomica S.A., Madrid, Spain): a 450 bp fragment of L1 ORF region was amplified utilising the MY09/11 consensus primers in the thermocycler CeneAmp 2400. An internal control and endogenous human CFTR gene were co-amplified. Detection and typing of amplified products: RFLP in high resolution 2% agarose gel.
Results: There were 157 samples positives from 143 patients: 129 with one HPV genotype, 24 with two and four with more than two genotypes. The more frequents genotypes detected were HPV16 (25.2% of patients), HPV6 (22.4%), HPV61 (9.8%), HPV53 (9.1%) and HPV18 (7.7%). A total of 68 (47.5%) of the 143 patients had genotypes included in vaccine. Twenty-two patients (15.4%) had high grade cervical lesions, and 15 from these 22 patients (68.2%) associated with HPV16 and HPV18.
1The most frecuent HPV infection genotypes in our sanitary area were HPV16, HPV6 and HPV61.
2The quadrivalent HPV vaccine will possibly prevent 47.5% of HPV infections by any genotype and 32.2% by high risk genotypes.
3The reduction of HPV related CIN2, 3 or adenocarcinoma in situ is estimated at 68.2%.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|